Anti-IL-6

Mechanism

Related News

argenx Reports $1.3B Q1 2026 Revenue, PDUFA Date Set for May 10 in Seronegative gMG

May 07, 2026

argenx reported $1.3B in Q1 2026 global product net sales (63% YoY growth). The FDA PDUFA target date for seronegative gMG is May 10, 2026. Positive ADAPT OCULUS results support an oMG label expansion. Pipeline milestones include myositis readout in Q3 2026 and MMN readout in Q4 2026.

Biomarkers and T Cell Traits Emerge as Key Predictors of Cancer Immunotherapy Response

Feb 17, 2026

New research identifies circulating tumor-reactive T cell characteristics and inflammatory biomarkers as predictive indicators for immune checkpoint inhibitor response in cancer patients, while the PD-L1 testing market is projected to reach $36.44 billion by 2032.